Asgpr-binding compounds for the degradation of extracellular proteins
US-2024424108-A1 · Dec 26, 2024 · US
US2016347767A1 · US · A1
| Field | Value |
|---|---|
| Publication number | US-2016347767-A1 |
| Application number | US-201615006940-A |
| Country | US |
| Kind code | A1 |
| Filing date | Jan 26, 2016 |
| Priority date | Nov 19, 2010 |
| Publication date | Dec 1, 2016 |
| Grant date | — |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Compounds and methods in the fields of chemistry and medicine are disclosed. Some of the disclosed embodiments include compounds, compositions and methods of using heterocycle amines. Some of the disclosed embodiments include heterocycle amines useful to treat inflammatory disorders.
Opening claim text (preview).
What is claimed is: 1 . A compound of Formula (I): or a salt, ester, amide, or prodrug thereof, wherein is a single or double bond; W is selected from CH, CH—CH, O, S, NR 6 , and CO; Y is N or CR 9 ; Z is N or C, and Z is N if W is CH and Y is CR 9 ; R 4 is selected from hydrogen, halogen, OR 6 , CN, NR 7 R 8 , CH 2 OR 6 , an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted non-aromatic ring, an optionally substituted carbocycle, an optionally substituted C 1 -C 6 alkyl, an optionally substituted C 1 -C 6 haloalkyl, an optionally substituted C 1 -C 6 heteroalkyl, an optionally substituted C 1 -C 6 alkenyl, an optionally substituted C 1 -C 6 alkynyl, CO 2 R 6 , SO 3 R 6 , SO 2 R 6 and SO 2 NR 7 R 8 ; R 5 is selected from hydrogen, halogen, OR 6 , an optionally substituted C 1 -C 6 alkyl, an optionally substituted C 1 -C 6 haloalkyl, an optionally substituted C 1 -C 6 heteroalkyl, an optionally substituted C 1 -C 6 haloheteroalkyl, an optionally substituted C 1 -C 6 alkenyl, and an optionally substituted C 1 -C 6 alkynyl; or R 4 and R 5 are linked to form an optionally substituted non-aromatic ring; each R 6 is independently selected from an optionally substituted aryl, an optionally substituted heteroaryl, and an optionally substituted non-aromatic ring, each optionally fused with a substituted aryl or a substituted heteroaryl, hydrogen, an optionally substituted C 1 -C 10 alkyl, an optionally substituted C 1 -C 10 haloalkyl, and an optionally substituted C 1 -C 10 heteroalkyl; each R 7 and R 8 is independently selected from an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted non-aromatic ring, each optionally fused with a substituted aryl or a substituted heteroaryl, hydrogen, an optionally substituted C 1 -C 10 alkyl, an optionally substituted C 1 -C 10 haloalkyl, an optionally substituted C 1 -C 10 alkenyl, an optionally substituted C 1 -C 10 alkynyl, and an optionally substituted C 1 -C 10 heteroalkyl, or R 7 and R 8 are linked to form an optionally substituted non-aromatic ring; R 9 is selected from hydrogen, halogen, OR 6 , CN, NR 7 R 8 , CH 2 OR 6 , an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted non-aromatic ring, an optionally substituted C 1 -C 6 alkyl, an optionally substituted C 1 -C 6 haloalkyl, an optionally substituted C 1 -C 6 heteroalkyl, an optionally substituted C 1 -C 6 alkenyl, an optionally substituted C 1 -C 6 alkynyl, CO 2 R 6 , SO 3 R 6 , and SO 2 NR 7 R 8 ; A is an optionally substituted aryl or an optionally substituted heteroaryl group; each optionally substituted group is either unsubstituted or substituted with one or more groups independently selected from alkyl, heteroalkyl, alkenyl, alkynyl, haloalkyl, heterohaloalkyl, aryl, arylalkyl, heteroaryl, non-aromatic ring, hydroxy, alkoxy, aryloxy, mercapto, alkylthio, arylthio, cyano, halo, carbonyl, thiocarbonyl, O-carbamyl, N-carbamyl, O-thiocarbamyl, N-thiocarbamyl, C-amido, N-amido, S-sulfonamido, N-sulfonamido, C-carboxy, O-carboxy, isocyanato, thiocyanato, isothiocyanato, nitro, silyl, trihalomethanesulfonyl, ═O, ═S, amino, and protected derivatives of amino groups. 2 . The compound of claim 1 , wherein R 4 is selected from hydrogen, halogen, OR 6 , CN, NR 7 R 8 , CH 2 OR 6 , an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted non-aromatic ring, an optionally substituted carbocycle, an optionally substituted C 1 -C 6 alkyl, an optionally substituted C 1 -C 6 haloalkyl, an optionally substituted C 1 -C 6 heteroalkyl, an optionally substituted C 1 -C 6 alkenyl, an optionally substituted C 1 -C 6 alkynyl, CO 2 R 6 , SO 3 R 6 , SO 2 R 6 and SO 2 NR 7 R 8 3 . The compound of claim 1 , wherein if R 4 is pyrazolyl, the pyrazolyl is not substituted with aryl or heteroaryl groups. 4 . The compound of claim 1 , wherein if R 4 is oxazolyl, isoxazolyl, or imidazoyl, the oxazolyl, isoxazolyl, or imidazoyl radical is not substituted with aryl or heteroaryl groups. 5 . The compound of claim 1 , represented by Formula (I-A): or a salt, ester, amide, or prodrug thereof, wherein X is N or CR 5 ′, wherein R 5 ′ is selected from hydrogen, halogen, OR 6 , an optionally substituted C 1 -C 6 alkyl, an optionally substituted C 1 -C 6 haloalkyl, an optionally substituted C 1 -C 6 heteroalkyl, an optionally substituted C 1 -C 6 haloheteroalkyl, an optionally substituted C 1 -C 6 alkenyl, and an optionally substituted C 1 -C 6 alkynyl; R 1 is selected from hydrogen, halogen, OR 6 , CN, NR 7 R 8 , CH 2 OR 6 , CH 2 NR 7 R 8 , an optionally substituted C 1 -C 6 alkyl, an optionally substituted C 1 -C 6 haloalkyl, an optionally substituted C 1 -C 6 alkenyl, an optionally substituted C 1 -C 6 alkynyl, an optionally substituted C 1 -C 6 heteroalkyl, CO 2 R 6 , CONR 7 R 8 , SO 3 R 6 , and SO 2 NR 7 R 8 ; R 2 and R 3 are independently selected from hydrogen, halogen, OR 6 , NR 7 R 8 , an optionally substituted C 1 -C 6 alkyl, an optionally substituted C 1 -C 6 haloalkyl, an optionally substituted C 1 -C 6 alkenyl, an optionally substituted C 1 -C 6 alkynyl, and an optionally substituted C 1 -C 6 heteroalkyl. 6 . The compound of claim 1 , represented by Formula (II): or a salt, ester, amide, or prodrug thereof. 7 . The compound of claim 1 , represented by Formula (III): or a salt, ester, amide, or prodrug thereof, wherein X is N or CR 5 ′, wherein R 5 ′ is selected from hydrogen, halogen, OR 6 , an optionally substituted C 1 -C 6 alkyl, an optionally substituted C 1 -C 6 haloalkyl, an optionally substituted C 1 -C 6 heteroalkyl, an optionally substituted C 1 -C 6 haloheteroalkyl, an optionally substituted C 1 -C 6 alkenyl, and an optionally substituted C 1 -C 6 alkynyl; R 1 is selected from hydrogen, halogen, OR 6 , CN, NR 7 R 8 , CH 2 OR 6 , CH 2 NR 7 R 8 , an optionally substituted C 1 -C 6 alkyl, an optionally substituted C 1 -C 6 haloalkyl, an optionally substituted C 1 -C 6 alkenyl, an optionally substituted C 1 -C 6 alkynyl, an optionally substituted C 1 -C 6 heteroalkyl, CO 2 R 6 , CONR 7 R 8 , SO 3 R 6 , and SO 2 NR 7 R 8 ; R 2 and R 3 are independently selected from hydrogen, halogen, OR 6 , NR 7 R 8 , an optionally substituted C 1 -C 6 alkyl, an optionally substituted C 1 -C 6 haloalkyl, an optionally substituted C 1 -C 6 alkenyl, an optionally substituted C 1 -C 6 alkynyl, and an optionally substituted C 1 -C 6 heteroalkyl. 8 . The compound of claim 1 , wherein W is S. 9 . The compound of claim 7 , wherein X is N. 10 . The compound of claim 1 , wherein Y is CR 9 . 11 . The compound of claim 1 , wherein R 4 is selected from the group consisting of pyridyl, pyrazolyl, cyano, triazolyl, and oxazolyl. 12 . The compound of claim 1 , wherein Y is N. 13 . The compound of claim 1 , wherein R 4 is selected from the group consisting of pyridyl, pyrazolyl, pyrimidinyl, pyridazinyl, and C 1 -C 6 al
having a nitrogen attached in position 2, e.g. clonidine · CPC title
condensed with carbocyclic rings or ring systems · CPC title
containing three or more hetero rings · CPC title
not condensed and containing further heterocyclic rings · CPC title
condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.